News

Medicines Development is currently coordinating an international collaboration between Opal Therapeutics Inc. (Opal) and Massachusetts General Hospital (MGH) to develop a novel immunotherapy to treat HIV. The collaboration involves the Ragon Institute of MGH, MIT and Harvard, Oxford University and the St Stephen’s AIDS Trust (Chelsea and Westminster Hospital). The first in human clinical trial is currently being conducted in London Sponsored by Medicines Development.